Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL Post author: Post published:March 17, 2026 Post category: Continue ReadingConsolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Post author: Post published:March 1, 2026 Post category: Continue ReadingA Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy Post author: Post published:March 1, 2026 Post category: Continue ReadingA Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Post author: Post published:March 1, 2026 Post category: Continue ReadingFludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Cellular Therapy for In Utero Repair of Myelomeningocele – The CuRe Trial Post author: Post published:March 1, 2026 Post category: Continue ReadingCellular Therapy for In Utero Repair of Myelomeningocele – The CuRe Trial
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV) Post author: Post published:March 1, 2026 Post category: Continue ReadingA Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs Post author: Post published:March 1, 2026 Post category: Continue ReadingLeading in MPNs Beyond Ruxolitinib in Combo With T-Regs
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL) Post author: Post published:March 1, 2026 Post category: Continue ReadingT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)
CAR-T Cells for HIV Infection Post author: Post published:March 1, 2026 Post category: Continue ReadingCAR-T Cells for HIV Infection
